Cardiology Fellow @MonteHeart | @EinsteinMed | @UChicago Biochem | Interested in humans, computers, and what they know about each other
New York, NY
Joined January 2021
- Tweets212
- Following1.1K
- Followers172
- Likes568
David Flomenbaum, MD, MS retweeted
Welcome to the MonteHeart family! We are thrilled to introduce our new cardiology fellows and excited for all the learning, collaboration, and innovation ahead
@AdityaDewanjee_ @SakthisuryaP @NathalieRosasMD
@AlexandrinaDan @Aneel_Maini @gal_rubinstein
@MatteoSturlaM @panos_zb
David Flomenbaum, MD, MS retweeted
Excited to welcome an incredible new group of Montefiore cardiology fellows!!
@MonteHeart @MontefioreNYC @EinsteinMed @aschenonegiugni
@SanyaChhikara @kaurarpanjeetMD @Swagata_P @SpringMD @bhalla_js @SaraswatiUshasi @DFlomenbaum @KayvonGhoreshi @BrownDonclair @JustinSongMD
🥰🥰🥰
We are beyond excited to welcome this stellar new class of cardiology fellows! 💫🫀🎉 Congratulations and welcome to MonteHeart! #cardiology #montefiore #monteheart #matchday @aschenonegiugni @GGreenbergMD @CardioMDPhD @barillas_irene @CrisZamoraMD @ZhanglilyA
David Flomenbaum, MD, MS retweeted
Interested in using LLMs to automate writing clinical notes?
Remember stories like this, which happen all the time.
Writing = thinking. LLMs can and do help us think, but not if they are implemented thoughtlessly.
David Flomenbaum, MD, MS retweeted
🧵regarding the introducer sheath commonly known as a 'Cordis' catheter.
We'll go over what it was originally designed for and why it ended up being adopted by other specialties for entirely different reasons.
Also we'll look at its accessories and see what's inside one.
(1/ )
David Flomenbaum, MD, MS retweeted
"Is there a doctor on the plane?"✈️🩺
Responding to in-flight medical emergencies.
#MedTwitter
David Flomenbaum, MD, MS retweeted
The "yo-yo diet" that alternates high and low fat markedly accelerates atherosclerosis compared with a continuous high fat diet
nature.com/articles/d41586-0… @NatureNV @justsaysinmice
Two independent studies in mice highlight the profound impact of diet on the innate immune response
@danrader333 @ktc_phd
David Flomenbaum, MD, MS retweeted
4 more performances to see @MontefioreIm's very own Dr. Sarah Tupchong in @lifelinemusical off-Broadway @signatureinnyc. Kudos to Sarah for contributing her onstage talents while shining as a 2nd-year resident!
ALT Dr. Sarah Tupchong, bottom row, 2nd from left, with fellow chorus members of Lifeline the Musical outside the Signature Theater off-Broadway.
Check out our newest publication in @hrs_journal! heartrhythmjournal.com/artic…
Cool! AUROC of 0.95 for detection of HF compared against at-risk controls using a smartphone alone
jacc.org/doi/full/10.1016/j.…
“The ECG is just a test: a Bayesian approach to acute coronary occlusion”
David Flomenbaum, MD, MS retweeted
Things We Do for No Reason™: Routine respiratory pathogen panels for emergency department and hospitalized patients shmpublications.onlinelibrar…
David Flomenbaum, MD, MS retweeted
In this @JACCJournals #JACCAdvances editorial, @RBPatelMD and I discuss the clinical and subclinical risk factors a/w cryptogenic stroke.
Given the relationship between AF and stroke, impt to appropriately adjudicate AF clinically, and in future studies
authors.elsevier.com/sd/arti…
David Flomenbaum, MD, MS retweeted
🚀🫀Explore recent breakthroughs, future directions, and evaluation & infrastructure needs for #AI-augmented cardiovascular care. Learn more in our two-part review published in @JACCJournals #ACC24.
Part 1: jacc.org/doi/10.1016/j.jacc.…
Part 2: jacc.org/doi/10.1016/j.jacc.…
David Flomenbaum, MD, MS retweeted
EPIC-SR trial: In fully vaccinated patients with risk factors for severe disease and patients (vaccinated or unvaccinated) without such risk factors, nirmatrelvir–ritonavir did not significantly shorten the time to alleviation of Covid-19 symptoms. nej.md/49kLhq3
ALT Table 2. Time to Sustained Alleviation of All Targeted Signs and Symptoms through Day 28.
David Flomenbaum, MD, MS retweeted
Some exciting new GLP-1 drug randomized trial evidence for *potential* disease-modifying impact on #Parkinsons disease (there are none).
No progression of motor disability in the Rx group for 12 months.
nejm.org/doi/full/10.1056/NE…
